Authors

  • Alimov J.U.
  • Hakkulov E.B.
  • Кaratayev M.N.

Keywords:

Oncourology, epidemiology, diagnosis, treatment, androgen-deprivation therapy.

References

1. Alfred Witjes J, Max Bruins H, Carrión A, et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol. 2024;85(1):17-31. doi: 10.1016/j.eururo.2023.08.016

2. André T, Boni C, Mounedji-Boudiaf L, et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343-2351. doi:10.1056/NEJMoa03270

3. Cai X, Chen P, Yin X, Li Q. Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer. Article in Chinese. Zhongguo Fei Ai Za Zhi.2002;5(6):427-428.doi:10.3779/j.issn.1009-3419.2002. 06.09.

4. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Harrap KR. Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev. 1985;12(suppl A):51-57. doi:10.1016/0305-7372(85)90018-0

5. de Castria TB, da Silva EM, Gois AF, Riera R. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2013;(8): CD009256. doi: 10.1002/14651858.CD009256.pub2

6. Dingemans AC, Früh M, Ardizzoni A, et al; ESMO Guidelines Committee. Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(7):839-853. doi: 10.1016/j.annonc.2021.03.207

7. Fuwa N, Kodaira T, Furutani K, et al. Intra-arterial chemoradiotherapy for locally advanced oral cavity cancer: analysis of therapeutic results in 134 cases. Br J Cancer. 2008;98(6):1039-1045. doi: 10.1038/sj.bjc.6604272

8. Galsky MD, Chen GJ, Oh WK, et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol. 2012;23(2):406-410. doi:10.1093/annonc/mdr156

9. Gosling CJ, Solanes A, Fusar-Poli P, Radua J. metaumbrella: The first comprehensive suite to perform data analysis in umbrella reviews with stratification of the evidence. BMJ Ment Health. 2023;26(1): e300534.doi:10.1136/bmjment-2022-300534

10. Guan J, Li Q, Zhang Y, et al. A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN). Oncotarget. 2016;7(6):7110-7119. doi:10.18632/oncotarget.685

11. Hendriks LE, Kerr KM, Menis J, et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Non–oncogene-addicted metastatic non–small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):358-376. doi: 10.1016/j.annonc.2022.12.013

12. Jiang Z., Woda B.A., Wu C.L. et al. Discovery and Clinical Application of a Novel Prostate Cancer Marker // Amer. J. Clin. Pathol. – 2004. – Vol. 122. – P. 275–289. doi:10.1309/EJUY-UQPE-X1MG-68MK.

13. Klastersky J, Sculier JP, Lacroix H, et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 1990;8(9):1556-1562. doi:10.1200/JCO.1990.8.9.1556

14. Lorusso D, Xiang Y, Hasegawa K, et al; ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet. 2024;403 (10434):1341-1350. doi:10.1016/S0140-6736(24)00317-9

15. Muggia FM, Bonetti A, Hoeschele JD, Rozencweig M, Howell SB. Platinum antitumor complexes: 50 years since Barnett Rosenberg’s discovery. J Clin Oncol. 2015;33(35):4219-4226. doi:10.1200/JCO.2015.60.7481

16. Ozols RF, Bundy BN, Greer BE, et al; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194-3200. doi:10.1200/JCO.2003.02.153